For laboratory and research use only. The following content is provided for scientific and educational purposes. Struck Bio Labs compounds are not intended for human consumption, injection, or clinical use and have not been evaluated by the Food and Drug Administration. This content does not constitute medical advice. See our full disclaimer.
One of the most frequently misunderstood aspects of the peptide supply landscape concerns the distinction between research-grade peptides and FDA-approved pharmaceutical peptides. These categories are legally and regulatorily distinct, and understanding that distinction is important for researchers, laboratory procurement teams, and anyone operating in the life sciences space. This overview explains the regulatory framework, the basis for the distinction, and what it means in practice, from a factual and educational standpoint.
What Is a Research Peptide?
A research-grade peptide is a synthetic or recombinant polypeptide supplied by a chemical or biochemical vendor for use in qualified laboratory investigation. Research-grade compounds are not FDA-approved drugs, not dietary supplements, and not cosmetics. They occupy a distinct regulatory category characterized by the following:
- Research Use Only (RUO) designation: This label indicates that the compound has not been evaluated by the FDA for safety or efficacy in humans and is not intended for diagnostic, therapeutic, or any clinical use. The RUO designation is a recognized category in FDA and laboratory supply contexts, with specific legal implications for how the compound may be marketed and sold.
- No clinical claims permitted: Suppliers of research-use-only compounds are prohibited under FDA and FTC law from making claims that the compound treats, cures, prevents, or improves any disease or health condition. The FTC competent and reliable scientific evidence standard for health claims requires controlled human clinical trials, a threshold that RUO suppliers do not meet for their products by definition.
- No approved indication: Research peptides have not undergone the Investigational New Drug (IND) application, clinical trial, or New Drug Application (NDA) or Biologics License Application (BLA) review processes required for FDA drug approval. They are chemical tools for scientific investigation, not approved therapies.
Published Research Landscape
The regulatory distinction between research chemicals and pharmaceutical drugs is well-documented in FDA guidance documents, Federal Register notices, and published regulatory science literature. Key reference sources include:
- FDA Guidance on Research Use Only and Investigational Use Only: The FDA has published guidance documents addressing the RUO label and its legal meaning, clarifying that RUO products cannot be used for clinical purposes without proper validation and clearance. The underlying principle is that “research use only” is a legally meaningful designation, not a marketing label, and applies broadly across chemical suppliers operating in regulated markets.
- FDA Warning Letters (2020-2026): The FDA has issued warning letters to multiple research peptide and compounded peptide vendors who made implied or explicit clinical claims for their products while labeling them “research use only.” These letters document that the RUO label does not provide protection when marketing materials, including website content, social media posts, or product descriptions, suggest human use or therapeutic benefit. Published FDA enforcement actions clearly define the regulatory boundary.
- FTC Health Products Compliance Guidance: The FTC guidance for health-related product marketers establishes that any claim implying a health benefit must be substantiated by competent and reliable scientific evidence, which for human health claims means controlled human clinical trials. RUO suppliers cannot make such claims for their products as sold.
Mechanism of Action
In the regulatory context, the relevant mechanism is the institutional and legal process that separates a research compound from a pharmaceutical drug. Understanding this process illustrates why the two categories are genuinely distinct and not simply a labelling choice.
The FDA drug approval pathway requires: (1) preclinical safety and efficacy data sufficient to support an Investigational New Drug (IND) application; (2) Phase I clinical trials establishing human safety and pharmacokinetics in healthy volunteers; (3) Phase II trials establishing preliminary efficacy and dose-finding in the target patient population; (4) Phase III trials demonstrating efficacy and monitoring adverse reactions in large randomized controlled trials; and (5) an NDA or BLA submission reviewed by the FDA for safety, efficacy, manufacturing quality (GMP compliance), and labelling. This process typically spans 10-15 years and requires substantial financial investment. FDA approval confers a specific, narrow indication. A drug approved for one condition is not thereby approved for another.
Research-grade peptide suppliers have not conducted this process. Their compounds are chemical tools for scientific inquiry, not drugs that have passed regulatory scrutiny for any clinical use.
Examples of peptides that exist in both research and pharmaceutical form illustrate the distinction concretely:
- GLP-S: As a research compound, GLP-S and related GLP-1 receptor agonist peptides are studied in academic and industrial research settings. As a pharmaceutical, GLP-S is the active ingredient in Ozempic (Novo Nordisk, FDA-approved for type 2 diabetes management) and Wegovy (FDA-approved for chronic weight management), products that have completed full clinical trial programmes and received specific FDA approvals for defined indications. The pharmaceutical versions are distinct from any research-grade compound.
- Bremelanotide: As a research compound, bremelanotide (PT-141) is investigated as a tool for melanocortin receptor biology research. As a pharmaceutical, bremelanotide is the active ingredient in Vyleesi (AMAG Pharmaceuticals, FDA-approved for hypoactive sexual desire disorder in premenopausal women), an approved drug that completed clinical trials and regulatory review for a specific clinical indication. The pharmaceutical and research-grade versions are legally distinct.
- Tesamorelin: As a research compound, tesamorelin (a growth hormone-releasing hormone analogue) has been studied in growth hormone axis research. As a pharmaceutical, tesamorelin is the active ingredient in Egrifta and Egrifta SV (Theratechnologies, FDA-approved for treatment of HIV-associated lipodystrophy), an approved drug with a narrow and defined clinical indication established through clinical trials.
The existence of a pharmaceutical version of a peptide does not confer any status on the research-grade version. They are legally distinct products in separate regulatory categories.
Supply Format for Research
Struck Bio Labs supplies research-grade peptides for qualified laboratory use only. The regulatory education above reflects why documentation, purity, and transparent supply practices matter to researchers: a well-characterized, high-purity compound with full COA documentation is a reliable research tool; an undocumented compound introduces uncontrolled experimental variables.
Frequently Asked Questions
Research Use Only (RUO) is a legally meaningful designation indicating that a compound has not been evaluated by the FDA for safety or efficacy in humans and is not intended for diagnostic, therapeutic, or clinical use. FDA guidance documents and enforcement actions make clear that the RUO label does not permit suppliers to make health claims or imply human use, and that the label itself does not provide regulatory protection if marketing materials imply clinical application. It is a genuine restriction on the intended use of the product, not a marketing disclaimer.
The same molecular structure can exist as both a research compound and as the active ingredient in an FDA-approved pharmaceutical. However, the two are distinct products in distinct regulatory categories. The FDA-approved pharmaceutical has undergone clinical trials, manufacturing quality review (GMP compliance), and received a specific approved indication. The research compound has not. They are not interchangeable, and the existence of a pharmaceutical version does not confer any approved status, safety data, or clinical indication on the research compound.
FDA and FTC law prohibits making drug claims, meaning treating, curing, preventing, or mitigating disease, for unapproved compounds. The FTC competent and reliable scientific evidence standard for health benefit claims requires controlled human clinical trials, evidence that RUO compound suppliers do not have for their products as sold. Making such claims while labelling products “research use only” does not provide protection under FDA or FTC enforcement. This has been demonstrated in multiple FDA warning letters issued to research peptide vendors over the 2020-2026 period.
A Certificate of Analysis (COA) is a batch-specific document prepared by the manufacturer or an independent third-party analytical laboratory that certifies the identity, purity, and concentration of a chemical compound. For research peptides, a COA typically includes HPLC chromatography (establishing purity as a percentage of the target compound) and mass spectrometry data (confirming molecular weight and identity). COA documentation is essential for research integrity. An undocumented or uncertified compound introduces uncontrolled variables into experimental outcomes and cannot be relied upon as a reproducible research tool. Struck Bio Labs provides COA documentation for its research catalog.
Compounding pharmacies operate under a separate FDA regulatory framework (Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act) that permits licensed pharmacists to prepare customized drug preparations for individual patients based on a valid prescription. Compounded peptide preparations are distinct from RUO research compounds; they are intended for human administration under medical supervision and must comply with USP standards and state pharmacy board regulations. Research peptide suppliers operate in the RUO category and their products are not intended for human administration. These are legally distinct supply chains with different regulatory obligations.
Struck Bio Labs applies third-party analytical testing, including HPLC purity analysis and mass spectrometry identification, to research vials and provides batch-specific COA documentation to qualified researchers. This testing infrastructure supports research integrity by ensuring that compounds are what they are represented to be at the documented purity level. Transparency in documentation is a foundational commitment for a responsible research-grade supplier operating in the current regulatory environment.
What does “for research use only” legally mean?
Research Use Only (RUO) is a legally meaningful designation indicating that a compound has not been evaluated by the FDA for safety or efficacy in humans and is not intended for diagnostic, therapeutic, or clinical use. FDA guidance documents and enforcement actions make clear that the RUO label does not permit suppliers to make health claims or imply human use, and that the label itself does not provide regulatory protection if marketing materials imply clinical application. It is a genuine restriction on the intended use of the product, not a marketing disclaimer.
Can a research peptide be the same molecule as an FDA-approved drug?
The same molecular structure can exist as both a research compound and as the active ingredient in an FDA-approved pharmaceutical. However, the two are distinct products in distinct regulatory categories. The FDA-approved pharmaceutical has undergone clinical trials, manufacturing quality review (GMP compliance), and received a specific approved indication. The research compound has not. They are not interchangeable, and the existence of a pharmaceutical version does not confer any approved status, safety data, or clinical indication on the research compound.
Why can research peptide suppliers not make health claims?
FDA and FTC law prohibits making drug claims, meaning treating, curing, preventing, or mitigating disease, for unapproved compounds. The FTC competent and reliable scientific evidence standard for health benefit claims requires controlled human clinical trials, evidence that RUO compound suppliers do not have for their products as sold. Making such claims while labelling products “research use only” does not provide protection under FDA or FTC enforcement. This has been demonstrated in multiple FDA warning letters issued to research peptide vendors over the 2020-2026 period.
What is a Certificate of Analysis and why does it matter?
A Certificate of Analysis (COA) is a batch-specific document prepared by the manufacturer or an independent third-party analytical laboratory that certifies the identity, purity, and concentration of a chemical compound. For research peptides, a COA typically includes HPLC chromatography (establishing purity as a percentage of the target compound) and mass spectrometry data (confirming molecular weight and identity). COA documentation is essential for research integrity. An undocumented or uncertified compound introduces uncontrolled variables into experimental outcomes and cannot be relied upon as a reproducible research tool. Struck Bio Labs provides COA documentation for its research catalog.
How do compounding pharmacies differ from research peptide suppliers?
Compounding pharmacies operate under a separate FDA regulatory framework (Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act) that permits licensed pharmacists to prepare customized drug preparations for individual patients based on a valid prescription. Compounded peptide preparations are distinct from RUO research compounds; they are intended for human administration under medical supervision and must comply with USP standards and state pharmacy board regulations. Research peptide suppliers operate in the RUO category and their products are not intended for human administration. These are legally distinct supply chains with different regulatory obligations.
What does Struck Bio Labs do to ensure research-grade quality?
Struck Bio Labs applies third-party analytical testing, including HPLC purity analysis and mass spectrometry identification, to research vials and provides batch-specific COA documentation to qualified researchers. This testing infrastructure supports research integrity by ensuring that compounds are what they are represented to be at the documented purity level. Transparency in documentation is a foundational commitment for a responsible research-grade supplier operating in the current regulatory environment.
Further Reading: What Are Research Peptides? • Purity & COA Testing • How to Read a COA
The above content is provided for informational and educational purposes relating to scientific research only. It does not constitute medical advice, a personal health recommendation, or a treatment protocol. Struck Bio Labs products are supplied for laboratory research use only. They are not intended for human consumption, injection, or clinical use, and have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. See our full disclaimer.